Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Pharmacogenomics of the triazole antifungal agent voriconazole.

Mikus G, Scholz IM, Weiss J.

Pharmacogenomics. 2011 Jun;12(6):861-72. doi: 10.2217/pgs.11.18. Review.

PMID:
21692616
2.

Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.

Mikus G, Schöwel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, Burhenne J, Weiss J, Thomsen T, Haefeli WE.

Clin Pharmacol Ther. 2006 Aug;80(2):126-35. Epub 2006 Jul 3.

PMID:
16890574
3.

Voriconazole therapeutic drug monitoring: focus on safety.

Pasqualotto AC, Xavier MO, Andreolla HF, Linden R.

Expert Opin Drug Saf. 2010 Jan;9(1):125-37. doi: 10.1517/14740330903485637. Review.

PMID:
20021293
4.

Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.

Moriyama B, Falade-Nwulia O, Leung J, Penzak SR, JJingo C, Huang X, Henning SA, Wilson WH, Walsh TJ.

Mycoses. 2011 Nov;54(6):e877-9. doi: 10.1111/j.1439-0507.2011.02016.x. Epub 2011 May 25. No abstract available.

5.

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.

Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, Mikus G.

Br J Clin Pharmacol. 2009 Dec;68(6):906-15. doi: 10.1111/j.1365-2125.2009.03534.x.

6.

Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.

Andrews E, Damle BD, Fang A, Foster G, Crownover P, LaBadie R, Glue P.

Br J Clin Pharmacol. 2008 Apr;65(4):531-9. doi: 10.1111/j.1365-2125.2007.03084.x. Epub 2008 Feb 21.

7.

Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.

Berge M, Guillemain R, Trégouet DA, Amrein C, Boussaud V, Chevalier P, Lillo-Lelouet A, Le Beller C, Laurent-Puig P, Beaune PH, Billaud EM, Loriot MA.

Eur J Clin Pharmacol. 2011 Mar;67(3):253-60. doi: 10.1007/s00228-010-0914-2. Epub 2010 Oct 31.

PMID:
21038076
8.

Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.

Hassan A, Burhenne J, Riedel KD, Weiss J, Mikus G, Haefeli WE, Czock D.

Ther Drug Monit. 2011 Feb;33(1):86-93. doi: 10.1097/FTD.0b013e31820530cd.

PMID:
21192313
9.

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.

Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, Haefeli WE, Mikus G.

J Clin Pharmacol. 2009 Feb;49(2):196-204. doi: 10.1177/0091270008327537. Epub 2008 Nov 25.

PMID:
19033450
10.

Pharmacokinetic/pharmacodynamic profile of voriconazole.

Theuretzbacher U, Ihle F, Derendorf H.

Clin Pharmacokinet. 2006;45(7):649-63. Review.

PMID:
16802848
11.

Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype.

Geist MJ, Egerer G, Burhenne J, Mikus G.

Antimicrob Agents Chemother. 2006 Sep;50(9):3227-8. No abstract available.

12.

Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.

Narita A, Muramatsu H, Sakaguchi H, Doisaki S, Tanaka M, Hama A, Shimada A, Takahashi Y, Yoshida N, Matsumoto K, Kato K, Kudo K, Furukawa-Hibi Y, Yamada K, Kojima S.

J Pediatr Hematol Oncol. 2013 Jul;35(5):e219-23. doi: 10.1097/MPH.0b013e3182880eaa. Erratum in: J Pediatr Hematol Oncol. 2014 Apr;36(3):252. Dosage error in article text.

PMID:
23588332
13.

Analysis of cytochrome P450 gene polymorphism in a lupus nephritis patient in whom tacrolimus blood concentration was markedly elevated after administration of azole antifungal agents.

Fujita Y, Araki T, Okada Y, Aomori T, Shimizu R, Tomizawa T, Hiromura K, Nojima Y, Nakamura T, Yamamoto K.

J Clin Pharm Ther. 2013 Feb;38(1):74-6. doi: 10.1111/jcpt.12004. Epub 2012 Sep 12.

PMID:
22971159
14.

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.

Driscoll TA, Yu LC, Frangoul H, Krance RA, Nemecek E, Blumer J, Arrieta A, Graham ML, Bradfield SM, Baruch A, Liu P.

Antimicrob Agents Chemother. 2011 Dec;55(12):5770-9. doi: 10.1128/AAC.00531-11. Epub 2011 Oct 3.

15.

The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.

Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L, Chen Y, Hu DL, Wang D, Zhou HH.

Eur J Clin Pharmacol. 2009 Mar;65(3):281-5. doi: 10.1007/s00228-008-0574-7. Epub 2008 Nov 4.

PMID:
18982321
16.

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.

Driscoll TA, Frangoul H, Nemecek ER, Murphey DK, Yu LC, Blumer J, Krance RA, Baruch A, Liu P.

Antimicrob Agents Chemother. 2011 Dec;55(12):5780-9. doi: 10.1128/AAC.05010-11. Epub 2011 Sep 12.

17.

Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.

Hyland R, Jones BC, Smith DA.

Drug Metab Dispos. 2003 May;31(5):540-7.

18.

In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3.

Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK Jr, Thakker DR.

Drug Metab Dispos. 2010 Jan;38(1):25-31. doi: 10.1124/dmd.109.029769.

19.

Voriconazole: a new triazole antifungal.

Sabo JA, Abdel-Rahman SM.

Ann Pharmacother. 2000 Sep;34(9):1032-43.

PMID:
10981251
20.

Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.

Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M.

Clin Pharmacol Ther. 2004 Jun;75(6):587-8. No abstract available.

PMID:
15179414

Supplemental Content

Support Center